Trial · NCT06958835
Linezolid Plus Standard of Care
NCT06958835, Not applicable, Recruiting, University Hospital, Basel, Switzerland
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Linezolid Plus Standard of Care. Trials, record NCT06958835. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06958835
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Linezolid Plus Standard of Care
- NCT number
- NCT06958835
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 606 participants, estimated
- Lead sponsor
- University Hospital, Basel, Switzerland
- Conditions
- Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
- Interventions
- Linezolid 600 mg, Placebo
- First posted
- 2025-05-06
- Last updated
- 2026-07-13
Source ClinicalTrials.gov
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Desirability of Outcome Ranking (DOOR) | From randomisation (day 1) until day 90 | The hierarchical composite endpoint DOOR will be calculated based on the following 4 criteria: 1. Alive at 90 days 2. Return to usual level of function by day 90 3. None of the following complications: Microbiological or clinical failure leading to treatment change; Serious adverse reaction; Adverse event leading to study drug discontinuation 4. Hospital length of stay The primary outcome will be expressed as the win ratio, i.e., the ratio of the number of times that participants in the intervention group have a lower DOOR compared to those in the control group. In this study, a pairwise comparison is used, i.e., every participant in the linezolid group is compared with every participant in the control group. When comparing two participants, the winner will be determined by the first component of the DOOR in which the two participants differ, the only exceptions being ties when both participants die or if they do not die but have the same length of hospitalisation. |
| Secondary | All-cause mortality | From randomisation (day 1) until day 90 | Proportion of patients who died from any cause during the duration of the study. |
| Secondary | Time to death | From randomisation (day 1) until day 90 | |
| Secondary | Level of function | From randomisation (day 1) until day 90 | Proportion of participants back to their usual level of function prior to the infection. |
| Secondary | Number of participants with microbiological failure leading to treatment change | From day 14 to day 90 (randomisation = day 1) | Any positive sterile site culture with Staphylococcus aureus (S. aureus) between 14 and 90 days after randomisation that leads to a change in treatment. A sterile site means any site of the body where microorganisms are usually absent, i.e. below the outer and inner colonised surfaces of the skin and mucous membranes. Positive sterile sites cultures include deep visceral and musculoskeletal abscesses obtained in a sterile manner. |
| Secondary | Number of participants with early microbiological failure leading to treatment change | From day 5 to day 13 (randomisation = day 1) | Any positive sterile site culture with S. aureus between 5 and 13 days after randomisation that leads to a change in treatment. A sterile site means any site of the body where microorganisms are usually absent, i.e. below the outer and inner colonised surfaces of the skin and mucous membranes. Positive sterile sites cultures include deep visceral and musculoskeletal abscesses obtained in a sterile manner. |
| Secondary | Number of participants with clinical failure leading to treatment change | From day 14 to day 90 (randomisation = day 1) | Newly identified focus of S. aureus between 14 and 90 days after randomisation as determined by the site investigator (or delegated physician) that leads to a change in treatment. This can incorporate clinical, radiological, microbiological and pathological findings. |
| Secondary | Number of participants with early clinical failure leading to treatment change | From day 5 to day 13 (randomisation = day 1) | Newly identified focus of S. aureus between 5 and 13 days after randomisation as determined by the site investigator (or delegated physician) that leads to a change in treatment. This can incorporate clinical, radiological, microbiological and pathological findings. |
| Secondary | Hospital length of stay | From randomisation (day 1) until day 90 | Duration of the index acute hospital stay from randomisation until the day of hospital discharge. Transfers to another acute care hospital for continuation of acute treatment will be included in the assessment of hospital length of stay. Days after transfer to rehabilitation centres or switch to outpatient parenteral ambulatory treatment will not be included in the acute hospital stay. |
| Secondary | Time to being discharged alive | From randomisation (day 1) until day 90 | For participants who die during the hospitalisation, 90 days will be recorded. |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42009378 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06958835
GET https://conductscience.org/api/trials/v1/NCT06958835/registered?page=2